Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix

Cancer Letters

Volumn 262, Issue 2, 2008, Pages 183-189

  Volgger, Birgit ^a   Aspisirengil, Coskun ^a   Genser Krimbacher, Elisabeth ^a   Ciresa Koenig, Alexandra ^a   Daxenbichler, Günter ^a   Fuchs, Dietmar ^a   Windbichler, Gudrun ^a   Marth, Christian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CEA; Cervical carcinoma; Neopterin; SCC Ag; TPA

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; NEOPTERIN; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MIDDLE AGED; NEOPTERIN; PROGNOSIS; SERPINS; SURVIVAL ANALYSIS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 40649105718     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.12.005     Document Type: Article

References (40)

1. Boyce J., Fruchter R.O., Nicastri A.D., Amliavegar P.C., Reinis M.S., and Nelson J.H. Prognostic factors in stage I carcinoma of the cervix. Gynecol. Oncol. 12 (1981) 154-165
2. Burghardt E., Pickel H., Haas J., and Lahousen M. Prognostic factors and operative treatment of stage IB to IIB cervical cancer. Am. J. Obstet. Gynecol. 156 (1987) 988-996
3. Van Bommell P.F.J., van Lindert A.C.M., Kock H.C.L.V., Leers W.H., and Neijt J.P. A review of prognostic factors in early-stage carcinoma of the cervix (FIGO IB and IIA) and implications for treatment strategy. Eur. J. Obstet. Gynecol. Reprod. Biol. 26 (1987) 69-84
4. Kato H., Morioka H., Tsutsui H., Aramaki S., and Torigoe T. Value of tumor antigen (TA-4) of squamous cell carcinoma in predicting the extent of cervical cancer. Cancer 50 (1982) 1294-1296
5. Scambia G., Panici P.B., Baiocchi G., Amoroso M., Foti E., Greggi S., and Mancuso S. The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy. Am. J. Obstet. Gynecol. 164 (1991) 631-636
6. Kato H., and Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 40 (1977) 1621-1628
7. Moll R. Epithelial tumor markers: cytokeratins and tissue polypeptide antigen (TPA). Curr. Topics Pathol. 77 (1987) 71-101
8. Ngan H.Y.S., Cheng G.T.S., Yeung W.S.B., Wong L.C., and Ma H.K. The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix. Gynecol. Oncol. 52 (1994) 63-68
9. Braun P.G., and Leyendecker G. Carcinoembryonic antigen in cervical cancer: a five year follow-up. Cancer Detect. Prev. 6 (1983) 249-253
10. Kjorstad K.E., and Orjasaester H. The prognostic value of CEA determination in the plasma of patients with squamous cell cancer of the cervix. Cancer 50 (1982) 283-287
11. Murr C., Widner B., Wirleitner B., and Fuchs D. Neopterin as a marker for immune system activation. Curr. Drug Metabol. 31 (2002) 75-87
12. Murr C., Fuith L.C., Widner B., Wirleitner B., Baier-Bitterlich G., and Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress?. Anticancer Res. 19 (1999) 1721-1728
13. Reibnegger G., Fuchs D., Fuith L.C., Hausen A., Werner E.R., Werner-Felmayer G., and Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect. Prevent. 15 (1991) 483-490
14. Melichar B., Solichova D., and Freedman R.S. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int. J. Gynecol. Cancer 16 (2006) 240-252
15. Bichler A., Fuchs C., Hausen A., Hetzel H., Reibnegger G., and Wachter H. Measurement of urinary neopterin in normal pregnant and non-pregnant women and in women with benign and malignant genital tract neoplasms. Arch. Gynecol. 233 2 (1983) 121-130
16. Bartel U., Rabe H., and Schulz-Pinkus M. Erste Erfahrungen mit Neopterinbestimmungen im Urin von Frauen mit Genital-und Mammatumoren. Zentrabl. Gynakol. 109 (1987) 1226-1232
17. Reibnegger G.J., Bichler A.H., Dapunt O., Fuchs D.N., Fuith L.C., Hausen A., Hetzel H.M., Lutz H., Werner E.R., and Wachter H. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res. 46 (1986) 950-955
18. Bleker O.P., Ketting B.W., van Wayjen-Eecen B., and Kloosterman G.J. The significance of microscopic involvement of the parametrium and/or pelvic lymph nodes in cervical cancer stages IB and IIA. Gynecol. Oncol. 16 (1983) 56-62
19. Ngan N.Y.S., Cheung A.N.Y., Lauder I.J., Wong L.C., and Ma H.K. Prognostic significance of serum tumour markers in carcinoma of the cervix. Eur. J. Gynaecol. Oncol. 17 (1996) 512-517
20. Tinga D.J., Bouma J., and Aalders J.G. Patients with squamous cell versus adeno (squamous) carcinoma of the cervix, what factors determine the prognosis?. Int. J. Gyn. Cancer 2 (1992) 83-91
21. Bethwaite P., Yeong M.L., Holloway L., Robson B., Duncan G., and Lamb D. The prognosis of adenosquamous carcinomas of the uterine cervix. Br. J. Obstet. Gynaecol. 99 (1992) 745-750
22. Gaze M.N., Kelly C.G., Dunlop P.R., Redpath A.T., Kerr G.R., and Cowie V.J. Stage IB cervical carcinoma: a clinical audit. Br. J. Radiol. 65 (1992) 1018-1024
23. Russell J.M., Blair V., and Hunter R.D. Cervical carcinoma: prognosis in young patients. Br. Med. J. 295 (1987) 300-303
24. Delgado G., Bundy B., Zaino R., Sevin B.U., Creasman W.T., and Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol. Oncol. 38 (1990) 352-357
25. Hale R.J., Wilcox F.L., Buckley C.H., Tindall V.R., Ryder W.D., and Logue J.P. Prognostic factors in uterine cervical carcinoma: a clinicopathological analysis. Int. J. Gyn. Cancer 1 (1991) 19
26. Mariani L., Iacovelli A., Vincenzoni C., Diotallevi F.F., Atlante M., and Lombardi A. Cervical carcinoma in young patients: clinical and pathological variables. Int. J. Gynaecol. Obstet. 41 (1993) 61-66
27. Duk J.M., Groenier H.K., de Brujin H.W.A., Hollema H., ten Hoor K.A., van der Zee A.G.J., and Aalders J.G. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J. Clin. Oncol. 14/1 (1996) 111-118
28. Inoue M., Fujita Y., Abe Y., Inoue Y., Ueda G., Tanizawa O., Minagawa J., Yamada Y.T., Ohashi K., and Ozaki M. Tissue polypeptide antigen as a tumor marker for gynecological malignancies. Nippon Sanka Fuginka Gakkai Zasshi 37 (1985) 1799-1805 Abstract, Publication in Japanese
29. Kornafel J., and Wawrzkiewicz M. Evaluation of diagnostic usefulness of CEA, hCG and SCC antigens in cervical cancer patients. Eur. J. Gynaecol. Oncol. 10 (1989) 319-322
30. Yabushita H., Ogawa Alk Masuda T., Noguchi M., Nakanishi M., and Ishihara M. Clinical significance of statistical discrimination employing serum TA-4, TPA and CEA levels in uterine cervical cancer. Nippon Sanka Fujinka Gakkai Zasshi 38 (1986) 1770 Abstract, Publication in Japanese
31. Paulick R., Caffier H., Horner G., Lang K., and Filbry E. Clinical significance of different serum tumor markers in gynecological malignancies. Cancer Detect. Prevent. 8 (1985) 115-120
32. Avall Lundquvist E.H., Sjovall K., Nilsson B.R., and Eneroth P.H. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. Eur. J. Cancer 28A (1992) 1695-1702
33. Juang C.M., Wang P.H., Yen M.S., Lai C.R., Ng H.T., and Yuan C.C. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage Ib and IIa squamous cell carcinoma of the uterine cervix. Gyn. Oncol. 76 (2000) 103-106
34. Yuan C.C., Wang P.H., Ng H.T., Tsai L.C., Juang C.M., and Chiu L.M. Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis. Eur. J. Gynaecol. Oncol. 23 (2002) 17-20
35. de Brujin G.W.A., Kuk J.M., van der Zee A.G.J., Pras E., Willemse P.H.B., Boonstra H., Hollema H., Mourits M.J.E., E de Vries E.G., and Aalders J.G. The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix. Tumour Biol. 19 (1998) 505-516
36. Gaarenstroom K.N., Bonfrer J.M.G., Korse C.M., Kenter G.G., and Kenemans P. Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer. Anticancer Res. 17 (1997) 2955-2958
37. Takeda M., Sakuragi N., Okamoto K., Todo Y., Minobe S., Nomura E., Negishi H., Oikawa M., Yamamoto R., and Fujimoto S. Preoperative serum SCC, CA125 and CA 19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet. Gynecol. Scand. 81 (2002) 451-457
38. Bae S.N., Namkoong S.E., Jung J.K., Kim C.J., Park J.S., Kim J.W., Lee J.M., and Kim S.J. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix. Gynecol. Oncol. 64 (1997) 418-424
39. Gaarenstroom K.N., Kenter G.G., Bonfrer J.M.G., Korse C.M., van de Vijver M.J., Fleuren G.J., and Trimbos J.B. Can initial serum Cyfra 21-1, SCC Antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?. Gynecol. Oncol. 77 (2000) 164-170
40. Molina R., Filella X., Auge J.M., Bosch E., Torne A., Pahisa J., Lejarcegui J.A., Rovirosa A., Mellado B., Ordi J., and Biete A. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Anticancer Res. 25 (2005) 1765-1771